12 Best Biotech Penny Stocks To Invest In Now

3. Geron Corporation (NASDAQ:GERN)

Number of Hedge Fund Investors: 29

Stock Price as of December 26: $3.34

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on the development and commercialization of innovative therapies such as telomerase inhibitors for hematologic malignancies (blood cancers). Geron Corporation (NASDAQ:GERN) has recently achieved a significant milestone with the FDA approval and commercial launch of RYTELO, a first-in-class telomerase inhibitor for the treatment of lower-risk myelodysplastic syndromes (MDS).

Geron Corporation (NASDAQ:GERN) is focusing on the commercialization of RYTELO in the United States. The company is expanding its reach by targeting more eligible patients and increasing awareness among healthcare providers (HCPs) through educational initiatives and market research. The company’s sales and marketing teams are working to reinforce the clinical benefits of RYTELO, including its high red blood cell transfusion independence rates and favorable safety profile.

Furthermore, Geron Corporation (NASDAQ:GERN)  is actively preparing for the potential launch of RYTELO in the European Union, with the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) reviewing the marketing authorization application which is expected to be completed by early 2025. Subject to regulatory approval, the company plans to commercialize RYTELO in select EU markets beginning in 2026. To facilitate this expansion, Geron Corporation (NASDAQ:GERN) is collaborating with experienced third parties to manage critical activities such as reimbursement, health technology assessments (HTA), market access, and distribution. This strategic approach aims to optimize patient access and revenues in prioritized countries, ensuring that RYTELO reaches those who need it most.

Geron Corporation (NASDAQ:GERN) is also advancing the pivotal Phase 3 IMpactMF trial in relapsed/refractory myelofibrosis (MF), which is expected to complete interim and final analyses in 2026 and 2027, respectively. A positive outcome in this trial could significantly expand the market opportunity for RYTELO and solidify its position as a transformative treatment in hematologic malignancies.